Nasal mucosal immunogenicity for the horse of a SeM peptide of Streptococcus equi genetically coupled to cholera toxin.
The intranasal immunogenicity of cholera toxin (CT) genetically coupled to peptide sequence aa236-334 (F3) of the SeM protein of Streptococcus equi was studied in five young adult Welsh ponies. All ponies made rapid CTB- and SeMF3-specific serum antibody responses following the first immunization. Specific nasal IgA responses were detected in two ponies 14 days after the first immunization, in another two 14 days after a second immunization on day 14, and in all ponies 28 days after a third immunization on day 42. SeMF3-specific antibody responses in sera and nasal washes were dominated by IgGb and IgA, respectively, and remained elevated for at least 140 days. Strong serum IgGa and IgG(T) responses were also observed. These antibody responses were qualitatively similar to those induced during recovery from equine strangles. Antibody responses in mucosal secretions were boosted in some ponies by immunizations subsequent to the first immunization, but antibodies in serum were never boosted. In vitro survival of S. equi was significantly reduced by SeMF3-specific antibodies in sera obtained 14 days after the second immunization but survival increased in sera collected following subsequent immunizations, possibly due to absence of synthesis of high affinity antibodies. Finally, the susceptibility of all immunized ponies to commingling challenge by S. equi indicated either that SeMF3 lacks protective epitopes or that the antibodies induced by the chimera were not at effective levels.
Sheoran
A S
AS
Gluck Equine Research Center, University of Kentucky, Lexington, KY 40546-0099, USA.
Artiushin
S
S
Timoney
J F
JF
D000281:Administration, Intranasal; D000818:Animals; D000907:Antibodies, Bacterial / Q000096:biosynthesis / Q000097:blood; D000942:Antigens, Bacterial; D001425:Bacterial Outer Membrane Proteins / Q000235:genetics* / Q000276:immunology*; D002352:Carrier Proteins / Q000235:genetics* / Q000276:immunology*; D002772:Cholera Toxin / Q000008:administration & dosage / Q000235:genetics* / Q000276:immunology*; D006734:Horse Diseases / Q000276:immunology / Q000517:prevention & control; D006736:Horses; D018928:Immunity, Mucosal; D009297:Nasal Mucosa / Q000276:immunology; D013290:Streptococcal Infections / Q000276:immunology / Q000517:prevention & control / Q000662:veterinary; D022541:Streptococcal Vaccines / Q000008:administration & dosage* / Q000235:genetics / Q000276:immunology; D018502:Streptococcus equi / Q000235:genetics* / Q000276:immunology*; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology
D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D001425:Bacterial Outer Membrane Proteins; D002352:Carrier Proteins; D022541:Streptococcal Vaccines; D014614:Vaccines, Synthetic; C014689:streptococcal M protein; D002772:Cholera Toxin